DIFFUSIO2N

Serial Number 97508583
732

Registration Progress

Application Filed
Jul 18, 2022
Under Examination
Feb 13, 2024
Approved for Publication
Dec 19, 2023
Published for Opposition
Dec 19, 2023
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Feb 13, 2026 12 days

Trademark Image

DIFFUSIO2N

Basic Information

Serial Number
97508583
Filing Date
July 18, 2022
Published for Opposition
December 19, 2023
Drawing Code
5

Status Summary

Current Status
Active
Status Code
732
Status Date
Aug 12, 2025
Application
Pending
Classes
005

Rights Holder

Diffusion Pharmaceuticals LLC

16
Address
Suite 201
300 East Main Street
Charlottesville, VA 22902

Ownership History

Diffusion Pharmaceuticals LLC

Original Applicant
16
Charlottesville, VA

Diffusion Pharmaceuticals LLC

Owner at Publication
16
Charlottesville, VA

Legal Representation

Attorney
Marya K. Jones

USPTO Deadlines

Next Deadline
12 days remaining
NOA E-Mailed - SOU Required
Due Date
February 13, 2026
Extension Available
Until August 13, 2026

Application History

28 events
Date Code Type Description Documents
Aug 13, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 12, 2025 EX3G S SOU EXTENSION 3 GRANTED Loading...
Aug 12, 2025 EXT3 S SOU EXTENSION 3 FILED Loading...
Aug 12, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 14, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 13, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Feb 13, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
Feb 13, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 12, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 13, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Aug 13, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 12, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 13, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 19, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 19, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 29, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 15, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 10, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 9, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 9, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 9, 2023 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Aug 9, 2023 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
May 9, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 9, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
May 9, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 2, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 9, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 21, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals, namely, drugs that increase tissue oxygenation, drugs that assist with cancer treatment, drugs that increase tissue oxygenation that enhance performance of mammals

Additional Information

Design Mark
The mark consists of the letters and number in the following order with the "2" as a subscript: Diffusio2n.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"DIFFUSION"